Neogen (NASDAQ:NEOG) Reaches New 12-Month High Following Strong Earnings

Shares of Neogen Corporation (NASDAQ:NEOG) reached a new 52-week high during trading on Friday following a stronger than expected earnings report. The company traded as high as $11.56 and last traded at $11.53, with a volume of 4761033 shares traded. The stock had previously closed at $9.40.

The company reported $0.09 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.03. The company had revenue of $225.30 million during the quarter, compared to analyst estimates of $212.35 million. Neogen had a positive return on equity of 2.78% and a negative net margin of 0.91%.The firm’s revenue for the quarter was down .1% compared to the same quarter last year. During the same period in the prior year, the business posted ($2.82) earnings per share.

Key Neogen News

Here are the key news stories impacting Neogen this week:

• Positive Sentiment: Neogen reported fiscal Q4 adjusted earnings of $0.09 per share, above the $0.05 analyst consensus and substantially better than the $2.82-per-share loss reported in the year-ago quarter. Revenue of $225.3 million also exceeded estimates of $212.35 million. Neogen Beats Q4 Earnings and Revenue Estimates
• Positive Sentiment: Management forecast fiscal 2027 revenue of $880 million to $885 million, above the $851.1 million consensus estimate. First-quarter fiscal 2027 revenue guidance of $207 million to $209 million also topped the $204.9 million consensus. Neogen Fiscal 2027 Guidance
• Positive Sentiment: The company expects fiscal 2027 adjusted EBITDA of approximately $180 million to $182 million, signaling anticipated improvement in profitability and supporting the favorable investor reaction. Neogen Fiscal 2026 Results
• Neutral Sentiment: Despite the earnings beat, quarterly revenue was essentially flat year over year, down 0.1%, indicating that the stronger outlook depends on future growth rather than current top-line acceleration.
• Neutral Sentiment: Analysts’ average price target is approximately $10.67, below the stock’s recent trading level, suggesting valuation and expectations may limit additional upside. Analysts Set Neogen Price Target
• Negative Sentiment: Neogen plans to increase research and development spending by roughly 50% in fiscal 2027. Although intended to support longer-term growth, the investment could pressure near-term margins and earnings.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. Wall Street Zen upgraded Neogen from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Weiss Ratings lowered shares of Neogen from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, July 24th. Two investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $10.67.

Institutional Trading of Neogen

Several institutional investors have recently added to or reduced their stakes in NEOG. UMB Bank n.a. lifted its stake in Neogen by 238.2% during the fourth quarter. UMB Bank n.a. now owns 6,422 shares of the company’s stock worth $45,000 after purchasing an additional 4,523 shares in the last quarter. Hantz Financial Services Inc. grew its stake in shares of Neogen by 816.9% in the fourth quarter. Hantz Financial Services Inc. now owns 7,592 shares of the company’s stock valued at $53,000 after buying an additional 6,764 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its holdings in shares of Neogen by 3,158.4% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 8,309 shares of the company’s stock valued at $58,000 after buying an additional 8,054 shares during the period. Los Angeles Capital Management LLC purchased a new stake in shares of Neogen in the 4th quarter valued at $65,000. Finally, Merit Financial Group LLC acquired a new position in Neogen during the 4th quarter worth about $71,000. Institutional investors and hedge funds own 96.73% of the company’s stock.

Neogen Trading Up 4.4%

The company has a 50 day moving average of $9.44 and a 200-day moving average of $9.62. The stock has a market cap of $2.62 billion, a price-to-earnings ratio of -401.33, a price-to-earnings-growth ratio of 5.16 and a beta of 1.80. The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.84 and a current ratio of 3.82.

Neogen Company Profile

Neogen Corporation is a global provider of food and animal safety products, offering a broad portfolio of diagnostic and testing solutions. Headquartered in Lansing, Michigan, the company develops and manufactures tests designed to detect foodborne pathogens, allergens and toxins in food, beverage and environmental samples. Since its founding in 1982, Neogen has focused on delivering rapid, accurate and user‐friendly assays to food processors, grain handlers and quality laboratories around the world.

In the food safety arena, Neogen’s product lineup includes immunoassay kits, molecular diagnostics and enrichment media for pathogens such as Salmonella, Listeria and E.